PRRT2 and early-onset autosomal dominant Alzheimer disease: Furthermore, the present results strengthen the evidence on pro-hypertrophic effects of PKC activators, which are currently being developed for various indications such as cancer and Alzheimer’s disease thus indicating that potent PKC activators exhibit a significant risk of cardiac adverse effects.